Menu
  • Join
  • Login
  • Contact
 

Search abstracts


TARGETING PROGRAMMED CELL DEATH-1 (PD-1)

  • At: 2015 FIP Congress in Düsseldorf (Germany)
  • Type: Presentation
  • By: HARVEY, R. Donald (Winship Cancer Institute of Emory University, Hematology/Medical Oncology, Avondale Estates, United States)
  • Co-author(s): R. Donald Harvey
  • Abstract:

    Therapeutic antibodies that block the programmed cell death protein-1 (PD-1) immune checkpoint pathway prevent T-cell downregulation and promote immune responses against a number of cancer types. The US FDA has approved pembrolizumab for the treatment of advanced melanoma and nivolumab for advanced melanoma and squamous cell non-small cell lung

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses